Accumulating studies have shown that IDH1 mutations are related to the occurrence and development of glioma (28), and IDH1 mutations are more common in LGG(WHO II, WHO III) than in GBM(WHO IV) (29). This evidence concerns the gene IDH1 and central nervous system cancer.